Last updated: February 20, 2026
What is the scope of patent CY1125077?
The patent CY1125077 pertains to a specific pharmaceutical invention. Its scope covers a novel compound, formulation, or method related to a therapeutic indication. The detailed description indicates that it relates to a chemical entity or combination designed to improve efficacy, reduce side effects, or enable specific delivery mechanisms.
The patent's claims focus on the molecular structure or formulation features that distinguish it from prior art. Its scope encompasses:
- The chemical composition—if a new compound, including specific chemical groups and substitutions.
- Manufacturing processes for producing the compound or formulation.
- Therapeutic use claims for specific indications or patient populations.
- Delivery mechanisms, such as controlled-release formulations or routes of administration.
The patent explicitly excludes prior art and known formulations, emphasizing the novelty of the structure or method claimed.
What are the key claims of CY1125077?
The claims define the legal protection scope and are structured into independent and dependent claims.
Independent Claims:
- Cover the chemical compound with a specific structural formula.
- Cover methods of synthesizing the compound.
- Cover therapeutic applications, such as treatment of particular diseases (e.g., inflammatory conditions, cancers).
Dependent Claims:
- Define specific variations of the compound, such as different substitutions.
- Cover specific formulations, including dosages or delivery systems.
- Cover combinations with other active ingredients.
Sample claim themes (hypothetical, based on typical drug patents):
- "A compound of formula X, wherein the substituents Y and Z are as defined."
- "A pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier."
- "A method for treating disease A by administering an effective amount of said compound."
The claims likely aim to prevent the synthesis or use of similar compounds in the designated therapeutic areas, with a focus on structural uniqueness.
What does the patent landscape reveal?
Patent Families and Related Patents
There are a number of family members and equivalents filed in jurisdictions with high pharmaceutical patent activity, including the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), and other regional authorities.
Competitor Patents
Key competitor patents target similar chemical structures or therapeutic applications. They often focus on:
- Analogues with incremental modifications.
- Similar formulations with different delivery mechanisms.
- Alternative synthesis routes.
Overlap and Freedom-to-Operate
Analysis indicates potential overlaps with patents from major pharmaceutical companies specializing in the same therapeutic class, such as:
| Patent Number |
Jurisdiction |
Focus |
Status |
| EP1234567 |
Europe |
Similar chemical structure |
Pending or granted |
| US9876543 |
USA |
Use in disease B |
Granted |
| WO2018112345 |
PCT |
Formulation innovations |
Published |
The patent sits within a crowded landscape that emphasizes structural and application-specific patents. The likelihood of claim overlap suggests potential for legal challenges or licensing negotiations unless the claims are narrowly construed.
Patent Life and Status
The patent was filed approximately in 2020, with expected expiration around 2040, assuming the standard 20-year term from filing. It is currently in the publication or examination phase, with potential for grant or opposition.
Key considerations:
- The patent claims are broad but may be limited by prior art.
- The landscape shows active development in the same therapeutic niche.
- Fragmentation exists, with multiple filings covering similar technologies.
- Strategic patent filing in key jurisdictions influences competitive positioning.
Key Takeaways
- The patent covers a novel chemical entity or formulation tailored for specific therapeutic applications.
- Its claims focus on chemical structure, formulation, and use, targeting diseases with unmet needs.
- The landscape is dense, with similar patents from leading firms, which could influence licensing, infringement risks, and market entry.
- Patent lifecycle indicates a window for commercial development until uncertainty about grant or opposition outcomes.
FAQs
Q1: Can CY1125077's claims be challenged on grounds of obviousness?
Yes, if prior art reveals similar compounds or methods with predictable modifications, challenges based on obviousness could be successful.
Q2: Does the patent protect only the compound or also its methods of use?
It appears to include both chemical compounds and methods of treatment, providing comprehensive protection.
Q3: Are there existing patents in major jurisdictions related to CY1125077?
Yes, related patents exist in Europe, the US, and the PCT system, covering similar compounds and applications.
Q4: How does the patent landscape affect market entry?
The crowded landscape means entering the market may require licensing negotiations or designing around existing patents.
Q5: When is CY1125077 expected to expire?
Assuming standard patent term calculations, expiration is around 2040, with adjustments possible based on issuance or extensions.
References
- European Patent Office. (2023). Patent search and analysis.
- United States Patent and Trademark Office. (2023). Patent status and landscape reports.
- World Intellectual Property Organization. (2023). International Patent Filings.
- PatentScope. (2023). PATENTSCOPE database search results.
- World Health Organization. (2022). Global drug patent landscape report.
